ERBB2 and triple-negative breast carcinoma: In the past year, another emerging treatment option for triple-negative breast carcinoma has become available: trastuzumab–deruxtecan, an antibody–drug conjugate that has demonstrated efficacy in tumors with low HER2 expression [69].